WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H530024
CAS#: 637328-69-9
Description: Tanogitran, also called BIBT986, is a coagulation factor Xa inhibitor potentially for the treatment of septic shock.
Hodoodo Cat#: H530024
Name: Tanogitran
CAS#: 637328-69-9
Chemical Formula: C25H31N7O3
Exact Mass: 477.25
Molecular Weight: 477.570
Elemental Analysis: C, 62.88; H, 6.54; N, 20.53; O, 10.05
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: BIBT-986, BIBT 986, BIBT986, Tanogitran
IUPAC/Chemical Name: N-((2R)-2-(2-((4-Carbamimidoylanilino)methyl)-1-methyl-1H-benzimidazol-5-yl)-1-oxo-1-(pyrrolidin-1-yl)propan-2-yl)glycine
InChi Key: MAOALPSHCIBFJZ-RUZDIDTESA-N
InChi Code: InChI=1S/C25H31N7O3/c1-25(29-15-22(33)34,24(35)32-11-3-4-12-32)17-7-10-20-19(13-17)30-21(31(20)2)14-28-18-8-5-16(6-9-18)23(26)27/h5-10,13,28-29H,3-4,11-12,14-15H2,1-2H3,(H3,26,27)(H,33,34)/t25-/m1/s1
SMILES Code: O=C(O)CN[C@](C)(C1=CC=C2C(N=C(CNC3=CC=C(C(N)=N)C=C3)N2C)=C1)C(N4CCCC4)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 477.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Remko M, Remková A, Broer R. Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors. Molecules. 2016 Feb 4;21(2). pii: E185. doi: 10.3390/molecules21020185. PubMed PMID: 26861270.
2: Aditya S. Oral and parenteral anticoagulants: new kids on the block. J Postgrad Med. 2012 Oct-Dec;58(4):275-85. doi: 10.4103/0022-3859.105448. Review. PubMed PMID: 23298923.
3: Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernández C, Vargas-Castrillón E. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis. 2011 Feb;5(1):33-59. doi: 10.1177/1753944710387808. Review. PubMed PMID: 21045018.